MarketCap
Facebook
X
Telegram
Tenax Therapeutics Operating Income | TENX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -56.4 M | -19.5 M | -8.23 M | 11.1 M | 32.7 M | 9.87 M | -8.56 M | -6.89 M | -9.21 M | -52.7 M | -14.8 M | -16.6 M | -5.19 M | -8.22 M | 10.6 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32.7 M | -56.4 M | -9.47 M |
Quarterly Operating Income Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.8 M | -16.6 M | -16.8 M | -11.8 M | -11.3 M | - | -4.62 M | -3.67 M | -3.91 M | - | 2.12 M | 1.24 M | 1.54 M | - | 2.92 M | 2.86 M | 2.72 M | - | 3.8 M | 1.96 M | 23.7 M | - | 2.23 M | 2.14 M | 2.67 M | - | 2.26 M | 1.82 M | 1.66 M | - | 1.55 M | 1.89 M | 1.22 M | - | 1.31 M | 3.01 M | 3.5 M | - | 4.5 M | 4.67 M | -5.71 M | -3.13 M | -3.1 M | -3.75 M | -3.11 M | -2.43 M | -4.14 M | -4.14 M | -2.42 M | -1.59 M | -2.11 M | -2.11 M | -1.59 M | -1.87 M | -683 K | -683 K | -1.68 M | 2.75 M | -2.05 M | 2.05 M | 2.43 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23.7 M | -18.8 M | -947 K |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Lyra Therapeutics
LYRA
|
-31 M | - | - | $ 24.9 M |  USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-104 M | - | - | $ 8.42 M | USA |
 |
Generation Bio Co.
GBIO
|
-142 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-28.9 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-272 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-136 M | - | - | $ 2.36 B | USA |
 |
Exicure
XCUR
|
-4.23 M | $ 1.09 | 3.81 % | $ 6.86 M | USA |
 |
Cellectis S.A.
CLLS
|
-33.1 M | $ 0.95 | -3.3 % | $ 95.3 M |  France |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 12.03 | 1.78 % | $ 3.59 B |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
98.3 M | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
409 M | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
-287 M | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-11.5 M | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
-45.9 M | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
-5.5 M | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
-185 M | $ 21.65 | -3.5 % | $ 1.24 B | Niderland |
 |
Stoke Therapeutics
STOK
|
-20.6 M | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
-178 M | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Annexon
ANNX
|
-216 M | $ 3.71 | -1.2 % | $ 575 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
1.51 B | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
MeiraGTx Holdings plc
MGTX
|
-106 M | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
4.17 B | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Burford Capital Limited
BUR
|
232 M | $ 3.24 | -3.72 % | $ 710 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
11.5 M | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
-11.1 M | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
-160 M | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
Evogene Ltd.
EVGN
|
-14 M | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
EyePoint Pharmaceuticals
EYPT
|
-243 M | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
-70.2 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 10.12 | 0.4 % | $ 289 M | USA |
 |
Foghorn Therapeutics
FHTX
|
-86.4 M | $ 2.04 | 2.0 % | $ 128 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
71.8 B | $ 13.76 | 4.13 % | $ 11.5 B |  India |
 |
Arcturus Therapeutics Holdings
ARCT
|
-76.3 M | $ 9.91 | 0.71 % | $ 271 M | Israel |
 |
Sanofi
SNY
|
6.34 B | $ 41.77 | 0.41 % | $ 51 B | France |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 31.74 | 1.73 % | $ 4.04 B | USA |
 |
Geron Corporation
GERN
|
-68.6 M | $ 1.15 | 2.23 % | $ 767 M | USA |
 |
Gossamer Bio
GOSS
|
-171 M | $ 9.2 | -4.27 % | $ 2.1 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-4.56 M | - | -3.76 % | $ 3.47 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-10.1 M | - | 3.16 % | $ 1.9 M | USA |